Stay updated on APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial
Sign up to get notified when there's something new on the APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial page.

Latest updates to the APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe study page now presents details for the APG-115 trial, including its design, participant criteria, treatment arms, outcome measures, and participating sites. It also identifies the study as active but not recruiting.SummaryDifference58%

- Check14 days agoChange DetectedThe ClinicalTrials.gov footer revision label changed from v3.7.2 to v3.8.0 while the study page continued to show a 403 Forbidden error.SummaryDifference0.2%

- Check21 days agoChange DetectedA sitewide banner announces NIH updates and FAQs about replacing “Artificial Intelligence” with “Super Intelligence” terminology during a transition. The study record itself remains unavailable behind a 403 error.SummaryDifference1%

- Check28 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.1 to v3.7.2, while the study page remains a 403 Forbidden error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check56 days agoChange DetectedRevision: v3.7.0 was added to indicate a new version of the study record. A broad set of study metadata items, including FDA-regulated status, IPD sharing, and location/investigator terms, were removed from the page.SummaryDifference18%

Stay in the know with updates to APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial page.